Cargando…
Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV(+) male participants on antiretroviral therapy (undetectable viral loads, CD4(+) T cells > 350 cells/μL) rece...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Clinical Investigation
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9057612/ https://www.ncbi.nlm.nih.gov/pubmed/35192543 http://dx.doi.org/10.1172/jci.insight.157031 |